|
Jul 21
|
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
|
|
Jul 21
|
Ocugen doses first subject in trial of modifier gene therapy candidate
|
|
Jul 18
|
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
|
|
Jul 17
|
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
|
|
Jun 24
|
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
|
|
Jun 23
|
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
|
|
Jun 17
|
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
|
|
Jun 16
|
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
|
|
Jun 11
|
Ocugen To Present at BIO International Convention 2025
|
|
May 27
|
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
|
|
May 26
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Apr 16
|
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?
|
|
Jan 17
|
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
|
|
Jan 16
|
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
|
|
Oct 10
|
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
|
|
Oct 9
|
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Oct 9
|
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
|
|
Oct 2
|
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
|
|
Sep 9
|
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
|
|
Jul 29
|
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
|